SEC Form 4 · accession 0001213900-18-012187

Citius Pharmaceuticals, Inc. · CTXR

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Financial Officer

Period of report

Sep 4, 2018

Accepted (ET)

Sep 6, 2018 · 4:06 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001506251

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	holding	—	—		—	60,353	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Purchase Common Stock)^F1	$1.62	Sep 4, 2018	A	70,000	A	—	Sep 4, 2028	Common Stock	70,000	70,000	D
Stock Option (Right to Purchase Common Stock)^F2	$3.45	holding	—	—	—	—	Sep 15, 2027	Common Stock	25,000	25,000	D
Stock Option (Right to Purchase Common Stock)^F3	$10.50	holding	—	—	—	—	Jun 6, 2026	Common Stock	48,267	48,267	D

F1One-third of the shares of the Company's common stock underlying the grant vest on each of the one-year, two-year and three-year anniversary of the vesting commencement date, September 4, 2018, provided that the Reporting Person provides continuous services to the Company as of each such vesting date.
F2On September 15, 2017 the Reporting Person was granted a ten-year option to purchase 25,000 shares of common stock at an exercise price of $3.45 per share. The options vest as follows: 8,333 shares vest on September 13, 2018, and then 694 shares per month for the next 24 months.
F3On July 6, 2016 the Reporting Person was granted a ten-year option to purchase 48,267 shares of common stock at an exercise price of $10.50 per share. The options vest as follows: 16,089 shares vest on July 7, 2017, and then 1,341 shares per month for the next 24 months

* All numbers reflect a 1-for-15 reverse stock split on June 9, 2017.